Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19637868 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | Non-Final OA | Janssen Biotech, Inc. |
| 19637933 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | Non-Final OA | Janssen Biotech, Inc. |
| 19447763 | Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor | Non-Final OA | AlbuNext, LLC |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | Final Rejection | ImmunityBio, Inc. |
| 16981168 | CELLULAR SIGNALING DOMAIN ENGINEERING IN CHIMERIC ANTIGEN RECEPTOR-MODIFIED REGULATORY T CELLS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 19393395 | LONG ACTING ALPHA4BETA7 TARGETING MOLECULE COMPOSITIONS FOR THE TREATMENT GASTROINTESTINAL INFLAMMATORY DISEASE | Non-Final OA | Paragon Therapeutics, Inc. |
| 18691685 | COMPOSITIONS OF CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALING MOLECULES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18344214 | SELF-ANTIGEN SPECIFIC T-CELLS AS VACCINES FOR AUGMENTING ENGRAFTMENT AND STABILITY OF AUTOLOGOUS TRANSFER | Non-Final OA | VANDERBILT UNIVERSITY |
| 18280561 | PROGNOSTIC PATHWAYS FOR HIGH RISK SEPSIS PATIENTS | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 19029764 | ALLOGENEIC DENDRITIC CELL (alloDC) TUMOR VACCINE, AND PREPARATION METHOD AND USE THEREOF | Non-Final OA | SHENZHEN FRONTIERGATE BIOTECHNOLOGY CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy